Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis

Author(s): Rusthoven KE, Hammerman SF, Kavanagh BD, Birtwhistle MJ, Stares M, et al.


Introduction. The pattern of failure (POF) after first-line systemic therapy in advanced non-small cell lung cancer (NSCLC) is unknown. We evaluate the POF in this setting to estimate the potential value of consolidative stereotactic body radiation therapy (SBRT). Materials and methods. The records of consecutive NSCLC patients presenting to the University of Colorado, Denver (UCD) between January 2005 and June 2008 were reviewed. Patients with measurable advanced stage NSCLC who received first-line systemic therapy and follow-up at UCD were eligible. In these patients, sites of disease at maximal response were evaluated for theoretical SBRT eligibility, based on institutional criteria. All patients were followed to extracranial progression. The POF was categorized as local (L) for lesions known prior to treatment or distant (D) for new lesions. Results. Among 387 consecutive lung cancer patients (all stages), 64 met the eligibility criteria and 34 were SBRT-eligible. Among all eligible patients, first extra-cranial progression was L-only in 64%, D-only in 9% and L + D in 27%. Among SBRT-eligible patients, POF was L-only in 68%, D-only in 14% and L + D in 18%. In SBRT-eligible patients, time to first progression was 3.0 months in those with L-only failure versus 5.7 month in those with any D failure (HR 0.44; 95% CI 0.22–0.90). Conclusions. The predominant POF in patients with advanced NSCLC after first-line systemic therapy is local-only. The current analysis suggests that SBRT could improve time to progression in a substantial proportion of patients. The estimated increase in time to progression using this approach would be approximately 3 months.

Similar Articles

Distribution of distant metastases from newly diagnosed non-small cell lung cancer

Author(s): Quint LE, Tummala S, Brisson LJ, Francis IR, Krupnick AS, et al.

Breast metastases from extramammary malignancies

Author(s): Bohman L, Bassett L, Gold R, Voet R

Metastases to the breast from extramammary malignancies

Author(s): Amichetti M, Perani B, Boi S

Metastatic tumors to the breast: Mammographic and ultrasonographic findings

Author(s): Lee SH, Park JM, Kook SH, Han BK, Moon WK

Metastases to the breast: Differential diagnosis from primary breast carcinoma

Author(s): Vergier B, Trojani M, De Mascarel I, Coindre JM, Le Treut A

Metastasis of primary lung carcinoma to the breast: a systematic review of the literature

Author(s): Mirrielees JA, Kapur JH, Szalkucki LM, Harter JM, Salkowski LR, et al.

EGFR-Mutated Breast Metastasis of Lung Adenocarcinoma: A Case Report

Author(s): Dansin E, Carnot A, Servent V, Daussay D, Robin YM, et al.

NCCN guidelines insights: Non-small cell lung cancer

Author(s): Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, et al.

Metastases to the breast from extramammary carcinomas

Author(s): Nielsen M, Ørnvold K, Andersen Ja, HenriksenFw, Kristensen Pb, et al.

Metastasis to the breast from extramammary malignancies: A report of four cases and a review of literature

Author(s): Vizcaino I, Torregrosa A, Higueras V, Morote V, Cremades A, et al.

Metastases to breast from primary lung cancer

Author(s): Babu KS, Roberts F, Bryden F, McCafferty A, Downer P, et al.

Local treatment of oligometastatic recurrence in patients with resected non-small cell lung cancer

Author(s): Yano T, Okamoto T, Haro A, Fukuyama S, Yoshida T, et al.

Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer

Author(s): Parikh RB, Cronin AM, Kozono DE, Oxnard GR, Mak RH, et al.

A case of metachronous metastasis to the breast from non-small cell lung carcinoma

Author(s): Yoon MY, Song CS, Seo MH, Kim MJ, Oh TY, et al.